World Congress Insulin Resistance
DIABETES & CARDIOVASCULAR DISEASE

FREE LIVE INTERACTIVE ONLINE
December 3–6, 2020

EARN CME ABIM-MOC CREDIT 33.5

Exploring New Frontiers In Metabolism – Tomorrow’s Clinical Science Today

JOINTLY PROVIDED
ADMINISTERED BY:
Welcome.

It is my pleasure to invite you to the 18th Annual World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC): Exploring New Frontiers in Metabolism — Tomorrow’s Clinical Science Today.

Following the restrictions imposed by the pandemic, the 18th Annual WCIRDC is going virtual! The live, interactive, online congress will take place on December 3–6, 2020 with free registration and 33.5 free CME/ABIM-MOC credits available.

The 4 day live-Online conference will continue to be available On Demand for 90 days. Following each session, there will be a live, interactive Q&A. The end of each day will conclude with a live panel summary discussion and interactive Q&A.

Since its inception, the congress has become the premier global meeting dedicated to metabolism-obesity, diabetes, lipids, HTN, CKD, CVD, HF, and NAFLD. It provides an exclusive opportunity for practicing professionals, clinical and basic scientists, researchers, and other clinicians to collaborate on emerging scientific and management strategies. The WCIRDC faculty consists of distinguished global experts who link research to clinical practice in a bench-to-bedside approach that is unique to this state-of-the-art program.

The conference includes joint sessions with the journals Metabolism and Lancet Diabetes & Endocrinology. Sessions will cover COVID-19, Heart Disease in Women, Lipotoxicity, Fatty liver, Lipids & Atherosclerosis, Contemporary Approach to Management of DM, CKD, CVD & HF Focus on GLP1ra, SGLT2i, and CGM, Obesity-Adults and pediatrics addressing Diets and bariatric surgeries.

Special sessions: Point-Counterpoint: Etiology of Insulin Resistance, debate: T2D Medications With CV Benefits for T1D, the Cardiometabolic Center Alliance, ACC Position on Managing CVD in DM, Genetics of T2D & CVD, Cancer and Medications Impact on Metabolism, Advance Technologies, Future Therapies for Diabetes, and Lifestyle in Disease Management.

Although virtual, the 18th WCIRDC congress will continue to have a robust e-Poster Hall, Oral Abstract Presentations, and an attractive Exhibit Hall, as well as Industry Supported CME & non-CME programs that, similar to the faculty of the congress, will feature some of the world’s best-known leaders and educators of their fields.

I look forward to having you join us for this exciting Live-Interactive-Online program on December 3–6, 2020!

Best regards,

Yehuda Handelsman, MD
Chair & Program Director
The World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC), now in its 18th year, is a unique and exciting multidisciplinary CME program. The Congress is the premier global meeting dedicated to diabetes, obesity, lipids, cardiovascular-kidney and liver disease linking basic research to clinical practice in pursuit of our theme: Exploring New Frontiers in Metabolism — Tomorrow’s Clinical Science Today.

This year, due to the pandemic, the Congress, originally planned for Los Angeles, goes virtual: Live-Interactive-Online over 4 days and will be available on demand for 90 days. For the first time, the registration will be free, including 33.5 CME & ABIM-MOC credits.

For nearly two decades, WCIRDC has brought researchers, physicians, clinicians, and other healthcare professionals together for a distinctive international program that bridges the latest developments from bench-to-bedside. “I heard it first at the Congress” is a frequent remark from the audience. WCIRDC offers attendees a unique experience to interact with the distinguished global faculty for a collaborative experience that explores the newest understanding of metabolic diseases and the development of future therapeutic modalities.

The Congress attracts state-of-the-art abstracts by young, up-and-coming researchers as well as recognized leaders from around the globe. The abstracts will be available for 90 days on the conference platform and published in Metabolism, a peer-reviewed journal, with over 40,000 unique monthly viewers worldwide, which is in the top 10% of endocrinology, diabetes, and metabolism journals.

Proceedings from the Congress are featured in global medical news venues such as Healio, Medscape, Endocrinology & Cardiology Today, Clinical Endocrinology News and more, while articles are being published in peer reviewed journals like Journal of Diabetes, Endocrine Practice, Metabolism, Diabetes & Vascular Disease Research, and others.

We welcome you to join us in this new phase of the Congress. We are looking forward to the same success, with you, in our new platform, just as we had in the past 17 years.

PROGRAM DESCRIPTION

The program is designed to evaluate the clinical and basic science aspects of diabetes, obesity, HTN, dyslipidemia, CVD, HF, CKD and related cardiometabolic conditions; focusing on basic science such as insulin resistance, hyperinsulinemia, fat, inflammation and clinical practice; understanding cardiometabolic conditions. The goal is to understand the pathophysiology of each condition and develop appropriate comprehensive clinical management plans.

Upon completion of this meeting, participants should be able to:
- Discuss COVID-19 and diabetes and Obesity
- Discuss Heart disease in women
- Describe the relationship between diabetes, obesity, and heart failure
- Address SGLT2i role in managing patients with CKD and HFREF
- Explain the role of PCSK9 inhibitors in preventing CV morbidity in people with established ASCVD
- Discuss fatty liver disease and its relationship to diabetes and CVD
- Evaluate the impact on clinical practice of recent CVD, CHF & CKD outcome trials
- Evaluate the impact on clinical practice of lipid CV outcome trials, including IMPROVE-IT, FOURIER, REDUCE-IT, ODYSSEY-OUTCOMES
- Analyze the Cardiorenal Syndrome
- Examine the impact of Coagulation in diabetes in prevention of CVD and CVA
- Describe technology in monitoring and reducing DM & ASCVD

PROGRAM OBJECTIVES

- Discuss The etiology of insulin resistance
- Discuss T1D obesity and CVD
- Discuss the effect of lipotoxicity and the pathophysiology of CVD
- Discuss the role of obesity in the development of cardiometabolic conditions
- Explain the roles of diabetes in the development of micro & macrovascular conditions: kidney disease, retinopathy, neuropathy, CVD and strokes
- Provide comprehensive management of diabetes, addressing obesity, hypertension, dyslipidemia and hyperglycemia while focusing on preventing ASCVD
- Discuss the role of GLP1ra in the management of diabetes, obesity, and prevention of ASCVD
- Evaluate SGLT2 inhibitors role in reducing cardiovascular morbidity & mortality in patients with and without T2D and at risk for or established CVD
- Evaluate SGLT2i role in managing patients with CKD and HFREF
- Explain the role of PCSK9 inhibitors in preventing CV morbidity in people with established ASCVD
- Discuss fatty liver disease and its relationship to diabetes and CVD
- Evaluate the impact on clinical practice of recent CVD, CHF & CKD outcome trials
- Evaluate the impact on clinical practice of lipid CV outcome trials, including IMPROVE-IT, FOURIER, REDUCE-IT, ODYSSEY-OUTCOMES
- Analyze the Cardiorenal Syndrome
- Examine the impact of Coagulation in diabetes in prevention of CVD and CVA
- Describe technology in monitoring and reducing DM & ASCVD

TARGET AUDIENCE

This educational initiative is designed for cardiologists, endocrinologists, internists, PCPs, diabetologists, OB/GYNs, pediatricians, gastroenterologists, oncologists, dietitians, nurse practitioners, physician assistants, pharmacists, and any other health care professionals who are interested in improving patients outcome.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 am</td>
<td>Welcome &amp; Introduction</td>
<td>Yehuda Handelsman, MD, Chair</td>
</tr>
<tr>
<td>8:10 am</td>
<td><strong>SESSION #1</strong> LIPOTOXICITY: THE PATHOPHYSIOLOGIC LINK BEHIND THE CARDIO-METABOLIC SYNDROME&lt;br&gt;&lt;br&gt;Chairs: Ralph DeFronzo, MD • Robert Chilton, DO</td>
<td>Robert Chilton, DO • Ralph DeFronzo, MD • Mikhail Kosiborod, MD • Derek LeRoith, PhD • Gina P. Lundberg, MD • Paul Zimmet, AO, MD, PhD</td>
</tr>
<tr>
<td>8:10 am</td>
<td>The Myocardium: Too Fat to be Fit</td>
<td>Robert Chilton, DO</td>
</tr>
<tr>
<td>8:30 am</td>
<td>Fatty Kidney: The Renal Manifestation of the Metabolic Syndrome</td>
<td>Ralph DeFronzo, MD</td>
</tr>
<tr>
<td>8:50 am</td>
<td>Nonalcoholic Fatty Liver Disease and Diabetes: Clinical Implications of “Foie Gras”</td>
<td>Kenneth Cusi, MD</td>
</tr>
<tr>
<td>9:10 am</td>
<td>Hormone Replacement Therapy, Atherosclerosis and Cardiovascular Disease: An Update</td>
<td>Eric Ravussin, PhD</td>
</tr>
<tr>
<td>9:30 am – 9:50 am</td>
<td>Live Q&amp;A Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>9:50 am</td>
<td><strong>SESSION #2</strong> HEART DISEASE IN WOMEN&lt;br&gt;&lt;br&gt;Chair: Tracey McLaughlin, MD • Matthew Budoff, MD</td>
<td>Tracey McLaughlin, MD • Matthew Budoff, MD</td>
</tr>
<tr>
<td>9:50 am</td>
<td>Sex Differences in Coronary Artery Calcium and Long-term CV Mortality</td>
<td>Martha Gulati, MD</td>
</tr>
<tr>
<td>10:10 am</td>
<td>Sex-Specific Differences in Risk Factors for Development of Heart Failure in Women</td>
<td>Gina Lundberg, MD</td>
</tr>
<tr>
<td>10:30 am</td>
<td>Estrogen Replacement Atherosclerosis and CVD</td>
<td>Howard Hodis, MD</td>
</tr>
<tr>
<td>10:50 am – 11:10 am</td>
<td>Live Q&amp;A Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>11:10 am – 11:55 am</td>
<td>PRODUCT THEATER Non-CME&lt;br&gt;&lt;br&gt;An Approach to Managing Lipids: Oral, Nonstatin Therapies for Lowering LDL-C&lt;br&gt;&lt;br&gt;Supported by: ESPERION Therapeutics</td>
<td>Paul Jellinger, MD</td>
</tr>
<tr>
<td>11:55 am</td>
<td><strong>SESSION #3</strong> LANCET DIABETES &amp; ENDOCRINOLOGY &amp; 18 WCIRDC JOINT SESSION: COVID-19, DM &amp; METABOLISM&lt;br&gt;&lt;br&gt;Chair: Marta Koch, PhD</td>
<td>Marta Koch, PhD</td>
</tr>
<tr>
<td>11:55 am</td>
<td>Two Pandemics in Collision: COVID-19 and Diabetes</td>
<td>Paul Zimmet, AO, MD, PhD</td>
</tr>
<tr>
<td>12:15 pm</td>
<td>Managing Patients with Diabetes and COVID-19</td>
<td>Stefan Bornstein, MD</td>
</tr>
<tr>
<td>12:35 pm</td>
<td>Obesity and Metabolic Surgery During and Beyond COVID-19</td>
<td>Gelttrude Mingrone,MD</td>
</tr>
<tr>
<td>12:55 – 1:15 pm</td>
<td>Live Q&amp;A Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>1:15 pm – 3:10 pm</td>
<td><strong>SESSION #4</strong> CME SYMPOSIUM HEART FAILURE AND KIDNEY DISEASE: THE NEXT EPIDEMICS&lt;br&gt;&lt;br&gt;Chairs: Michael Miller, MD • Yehuda Handelsman, MD</td>
<td>Yehuda Handelsman, MD, Chair • Maria Rosa Costanzo, MD • Mikhail Kosiborod, MD • Katherine Tuttle, MD • Muthiah Vaduganathan, MD</td>
</tr>
<tr>
<td>1:15 pm</td>
<td>Introduction</td>
<td>Yehuda Handelsman, MD, Chair</td>
</tr>
<tr>
<td>1:20 pm</td>
<td>Epidemiology and Traditional Management of HF and CKD</td>
<td>Maria Rosa Costanzo, MD</td>
</tr>
<tr>
<td>1:40 pm</td>
<td>The Future Is Here: Contemporary Approach to HF with a Focus on HFrEF</td>
<td>Mikhail Kosiborod, MD</td>
</tr>
<tr>
<td>2:00 pm</td>
<td>Revolution in the Management of Moderate to Severe CKD</td>
<td>Katherine Tuttle, MD</td>
</tr>
<tr>
<td>2:20 pm</td>
<td>Impact of Recent CVOTs on Contemporary Guidelines for HF and CKD</td>
<td>Muthiah Vaduganathan, MD</td>
</tr>
<tr>
<td>2:40 pm – 3:10 pm</td>
<td>Panel Discussion Q&amp;A: The Cardiorenal Syndrome — Is It More Than the Sum of the Individual Components?</td>
<td>Peter McCullough, MD, MPH</td>
</tr>
<tr>
<td>3:10 pm</td>
<td><strong>SESSION #5</strong> THE EFFECTS OF CANCER AND CANCER THERAPY ON METABOLIC DISORDERS&lt;br&gt;&lt;br&gt;Chairs: Derek LeRoith, MD PhD • Zachary Bloomgarden, MD</td>
<td>Derek LeRoith, MD, PhD • Zachary Bloomgarden, MD</td>
</tr>
<tr>
<td>3:10 pm</td>
<td>Overview of The Interaction Between Obesity, Diabetes and Cancer Therapy</td>
<td>Derek LeRoith, MD, PhD</td>
</tr>
<tr>
<td>3:30 pm</td>
<td>The Effect of Tyrosine Kinase, PI3K/mTor Inhibitors on Metabolism</td>
<td>Emily Gallagher, MD, PhD</td>
</tr>
<tr>
<td>3:50 pm</td>
<td>Immunobiologics Effect on Diabetes: Type 1 And Type 2</td>
<td>Kevan Herold, MD</td>
</tr>
<tr>
<td>4:10 pm – 4:30 pm</td>
<td>Live Q&amp;A Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>4:30 pm</td>
<td><strong>SESSION #5A</strong> INSULIN RESISTANCE &amp; T2D&lt;br&gt;&lt;br&gt;Chairs: Vivian Fonseca, MD</td>
<td>Vivian Fonseca, MD</td>
</tr>
<tr>
<td>4:30 pm</td>
<td>Important Role of Reduced Insulin Clearance in Pathogenesis of Type 2 Diabetes: Hypothesis and Experimental Confirmation in Man</td>
<td>Richard Bergman, PhD</td>
</tr>
<tr>
<td>4:50 pm – 5:00 pm</td>
<td>Live Q&amp;A Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>
## SESSION #6  PEDIATRIC OBESITY MANAGEMENT

**Chairs:** Sonia Caprio, MD • Alan Sinaiko, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 am</td>
<td>Pharmacotherapy in the Management of Pediatric Obesity</td>
<td>Aaron Kelly, PhD</td>
</tr>
<tr>
<td>8:20 am</td>
<td>Five-Year Outcomes of Gastric Bypass in Adolescents as Compared with Adults</td>
<td>Thomas Inge, MD, PhD</td>
</tr>
<tr>
<td>8:40 am</td>
<td>Sleeve Gastrectomy Impact on Cell Size and Genes from Adipose Tissue of Obese Adolescent Girls</td>
<td>Sonia Caprio, MD</td>
</tr>
<tr>
<td>9:00 am – 9:15 am</td>
<td>Live Q&amp;A Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>

## SESSION #7  WHAT SHOULD WE TARGET TO TREAT INSULIN RESISTANCE? – POINT-COUNTER-POINT

**Chairs:** Richard Bergman, PhD • Bart Staels, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:15 am</td>
<td>The Ceramide Pathway as a Target for Insulin Sensitization</td>
<td>Philipp Scherer, PhD</td>
</tr>
<tr>
<td>9:35 am</td>
<td>Diacylglycerols and acetyl-CoA as a Therapeutic Targets for Insulin Resistance and Type 2 Diabetes</td>
<td>Gerald Shulman, MD, PhD</td>
</tr>
<tr>
<td>9:55 am – 10:15 am</td>
<td>Live Q&amp;A Audience Vote/Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>

## SESSION #8  LIPIDS

**Chairs:** Paul Jellinger, MD • Ronald Krauss, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15 am</td>
<td>New Agents: PCSK9 siRNA (inclisiran) and Bempedoic Acid</td>
<td>Kausik Ray, MD</td>
</tr>
<tr>
<td>10:35 am</td>
<td>Triglycerides and CVD: Causal or Coincidental? Lessons from Recent Research</td>
<td>Robert Rosenson, MD, MD</td>
</tr>
<tr>
<td>10:55 am</td>
<td>The Role of LP(a) &amp; ANGPTL3 in Lipids Atherosclerosis and Cardiovascular Disease</td>
<td>Norman Lepor, MD</td>
</tr>
<tr>
<td>11:15 am – 11:35 am</td>
<td>Live Q&amp;A Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>

## SESSION #9  INSULIN FOCUSED MANAGEMENT OF DM - TODAY AND TOMORROW

**Chairs:** Vivian Fonseca, MD • Phil Scherer, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:20 pm</td>
<td>Islet Cell Preservation &amp; Replacement</td>
<td>Jay Skyler, MD</td>
</tr>
<tr>
<td>12:40 pm</td>
<td>Stem Cell Generated Human Islets- Rescue Diabetes Without a Device</td>
<td>Ronald Evans, PhD, MD</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>State of the Art Insulin Delivery Systems</td>
<td>George Grunberger, MD, MD</td>
</tr>
<tr>
<td>1:20 pm</td>
<td>Tomorrow’s New Insulin Today</td>
<td>Julia Rosenstock, MD</td>
</tr>
<tr>
<td>1:40 pm – 2:00 pm</td>
<td>Live Q&amp;A Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>

## SESSION #10  METABOLISM & 18 WCIRDc JOINT SESSION: HISTORY OF INSULIN RESISTANCE & METABOLISM

**Chair:** Christos Mantzoros, MD, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 pm</td>
<td>Introduction</td>
<td>Christos Mantzoros, MD, PhD</td>
</tr>
<tr>
<td>2:05 pm</td>
<td>Insulin Resistance and Cardiovascular Disease</td>
<td>James Sawers, MD</td>
</tr>
<tr>
<td>2:30 pm</td>
<td>Insulin resistance, NAFLD/NASH and CVD Risk</td>
<td>Dimitri Mikhailidis, MD</td>
</tr>
<tr>
<td>2:55 pm</td>
<td>Go with the Flow: Understanding Lipid Metabolism with Tracer Methods</td>
<td>Gerald Watts, PhD</td>
</tr>
<tr>
<td>3:20 pm – 3:40 pm</td>
<td>Live Q&amp;A Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>

## SESSION #11  ADVANCED TECHNOLOGIES & GENETICS FOR UNDERSTANDING & MANAGING IR & T2D

**Chair:** Daniel Einhorn, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:40 pm</td>
<td>Multiomics Analysis of IR vs IS Responses to Viral Infections, Exercise and Aging</td>
<td>Michael Snyder, PhD</td>
</tr>
<tr>
<td>4:00 pm</td>
<td>Continuous Glucose Monitoring for Precision Diets</td>
<td>Tracey McLaughlin, MD</td>
</tr>
<tr>
<td>4:20 pm</td>
<td>The Genetic Interrelationship Between T2D &amp; Coronary Heart Disease</td>
<td>Jerome Rotter, MD</td>
</tr>
<tr>
<td>4:40 pm – 5:00 pm</td>
<td>Live Q&amp;A Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>

## 5:00 pm – 6:00 pm DAY 2 SUMMARY SESSION

Sonia Caprio, MD • Vivian Fonseca, MD • George Grunberger, MD • Yehuda Handelsman, MD • Paul S. Jellinger, MD • Philipp E. Scherer, PhD
SESSION #12  NAFLD/NASH  
Chair: Sam Klein, MD

8:00 am  NASH- The Status of Diagnostics and Therapeutics  
Christos Mantzoros, MD, PhD
8:20 am  The Sexually Dimorphic Nature of NASH May Impact on Disease Progression and Responses To Drugs  
Bart Staels, PhD
8:40 am – 8:55 am  Live Q&A Panel Discussion

SESSION #13  ATHEROSCLEROSIS CARDIOVASCULAR DISEASE  
Chair: Norman Lepor, MD

8:55 am  Anti-Inflammatory Impact on Atherosclerosis: CVOT and Management Implications  
Jorge Plutzky, MD
9:15 am  Impact of Non Statin Drugs On Plaque Formation and Atherosclerosis  
Matthew Budoff, MD
9:35 am  GLP1ra and Atherosclerosis- Human Data at Last  
Peter Reaven, MD
9:55 am – 10:15 am  Live Q&A Panel Discussion

SESSION #14  OBESITY - INTERVENTIONS  
Chair: Tim Garvey, MD • Sam Klein, MD

11:00 am  The Influence of Dietary Carbs, Fat, And Quality on Ad Libitum Calorie Intake  
Kevin Hall, PhD
11:20 am  Future of Obesity Pharmacotherapy: New Drugs and New Targets  
W. Timothy Garvey, MD
11:40 am  Effects of Bariatric Surgery on Cardiovascular Events  
Philip Schauer, MD
12:00 pm  Does Intestinal Bypass Surgery Really Have Weight-Loss-Independent Therapeutic Metabolic Effects?  
Samuel Klein, MD
12:20 pm – 12:40 pm  Live Q&A Panel Discussion

SESSION #15  COVID-19 PATHOPHYSIOLOGY AND ADVANCED MANAGEMENT  
Chairs: Richard Pratley, MD • Matthew Weir, MD

1:25 pm  Pathophysiologi cal Basis & Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection  
Peter A McCullough, MD
1:45 pm  Sex Differences in Mortality from COVID-19 Pandemic  
Erin D. Michos, MD
2:05 pm  The Role of Neutralizing Antibody Therapy in the Management of COVID-19  
Ajay Nirula, MD, PhD
2:25 pm  Obesity & COVID 19  
Tracey McLaughlin, MD
2:45 pm – 3:05 pm  Live Q&A Panel Discussion

SESSION #16  CME SYMPOSIUM  EMERGING STANDARD OF CARE IN THE PREVENTION OF CARDIOVASCULAR MORBIDITY AND MORTALITY  
Supported by and Educational Grant from AMARIN

3:05 pm – 4:35 pm  Emerging Standard of Care In the Prevention of Cardiovascular Morbidity and Mortality  
Yehuda Handelsman, MD, Chair
3:05 pm  Introduction  
Deepak Bhatt, MD
3:10 pm  Primary and Secondary Prevention of CVD — Current standard of Care  
Neha Pagidipati, MD
3:30 pm  High TGL association with ASCVD- Epidemiology and pathophysiology  
Matthew Budoff, MD
3:50 pm  IPE impact on ASCVD Morbidity and Mortality  
Yehuda Handelsman, MD
4:10 pm  Lipid Guidelines IPE related  
Deepak Bhatt, mD
4:15 pm – 4:25 pm  The New Standard of Care — Case based  
Moderator: Deepak Bhatt, MD
4:25 pm – 4:45 pm  Panel Discussion Q&A: The New Standard of Care

4:35 pm – 5:35 pm  DAY 3 SUMMARY SESSION  
Matthew J. Budoff, MD • Yehuda Handelsman, MD • Samuel Klein, MD • Norman E. Lepor, MD • Tracey L. McLaughlin, MD • Richard E. Pratley, MD • Matthew R. Weir, MD
### SESSION #17  
**CARDIOVASCULAR DISEASE AND INSULIN RESISTANCE**  
**Chairs:** Jorge Plutzky, MD • Robert Chilton, DO  

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 am</td>
<td>Insulin Resistance And Thrombotic Risk: Implications For Therapeutic Approaches To Vascular Disease</td>
<td>Peter Grant, MD</td>
</tr>
<tr>
<td>8:20 am</td>
<td>Update of Recent CV Outcome Trials</td>
<td>Sanjay Kaul, MD</td>
</tr>
<tr>
<td>8:40 am</td>
<td>The ACC’s Expert Consensus Decision Pathway: Improving Cardiovascular Outcomes in Type 2 Diabetes</td>
<td>Brendan Everett, MD</td>
</tr>
<tr>
<td>9:00 am</td>
<td>The Future of Cardiometabolic Care is Here: Announcing Cardiometabolic Center Alliance</td>
<td>Mikhail Kosiborod, MD</td>
</tr>
<tr>
<td>9:20 am–9:40 am</td>
<td>Live Q&amp;A Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### SESSION #18  
**CONTEMPORARY ASPECTS OF DIABETES MANAGEMENT**  
**Chairs:** Peter Grant, MD • Jaime Davidson, MD  

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:40 am</td>
<td>Managing Type 2 Diabetes to Prevent CVD-CKD: SGLT-2i, GLP-1RA or Initial Combination of Both?</td>
<td>Francesco Giorgino, MD, PhD</td>
</tr>
<tr>
<td>10:00 am</td>
<td>Hypoglycemia Impact and Management</td>
<td>Vivian Fonseca, MD</td>
</tr>
<tr>
<td>10:20 am</td>
<td>The Role of CGM in Diabetes Update toward 2021</td>
<td>Richard Bergenstal, MD</td>
</tr>
<tr>
<td>10:40 am–10:59 am</td>
<td>Live Q&amp;A Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>10:59 am–11:30 am</td>
<td>PRODUCT THEATER Non-CME</td>
<td>Atherosclerotic Cardiovascular Disease (ASCVD) in Diabetes: Identifying High Risk and the Importance of Reducing the Burden of Elevated LDL-C Levels</td>
</tr>
</tbody>
</table>

### SESSION #19  
**OBESITY AND CVD IN TYPE 1 DIABETES**  
**Chairs:** George Grunberger, MD • Sonia Caprio, MD  

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 am</td>
<td>The Current Management of CV Risk factors in Type 1 Diabetes</td>
<td>Robert Eckel, MD</td>
</tr>
<tr>
<td>11:50 am</td>
<td><strong>DEBATE:</strong> SHOULD T2D MEDICATIONS WITH PROVEN CV BENEFITS BE USED IN T1D TO PREVENT ASCVD</td>
<td>Richard Pratley, MD</td>
</tr>
<tr>
<td>12:10 pm</td>
<td>Why Using T2D Medications with CVD Benefits is a Bad Idea for Type 1 Diabetes</td>
<td>David Nathan, MD</td>
</tr>
<tr>
<td>12:30 pm–12:50 pm</td>
<td>Live Q&amp;A Audience Vote/Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### SESSION #20  
**THE KIDNEY IN DIABETES**  
**Chairs:** Christian Mende, MD • Ralph DeFronzo, MD  

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:50 pm</td>
<td>KDIGO- Diabetes CKD and Hypertension New Guidelines</td>
<td>Matthew Weir, MD</td>
</tr>
<tr>
<td>1:10 pm</td>
<td>GLP1-RA and SGLT2i in the Treatment of Diabetic Nephropathy: What Does the Future Hold?</td>
<td>David Cherney, MD</td>
</tr>
<tr>
<td>1:30 pm–1:45 pm</td>
<td>Live Q&amp;A Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:45 pm–2:30 pm</td>
<td>PRODUCT THEATER Non-CME</td>
<td>VASCEPA (icosapent ethyl): Elevating the Standard of Care</td>
</tr>
</tbody>
</table>

### SESSION #21  
**ABSTRACT – ORAL PRESENTATION**  
**Chair:** Mikhail Kosiborod, MD  

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:45 pm</td>
<td>Lifestyle Modifications for Preventing and Treating Heart Failure</td>
<td>Monica Aggarwal, MD</td>
</tr>
<tr>
<td>4:05 pm</td>
<td>All We Need to Know about HFpEF</td>
<td>Carolyn Lam Su Ping, PhD</td>
</tr>
<tr>
<td>4:25 pm</td>
<td>Update on HFOT impact on Management - Sequencing vs Initial Combination of Medication</td>
<td>Javed Butler, MD</td>
</tr>
<tr>
<td>4:45 pm–5:05 pm</td>
<td>Live Q&amp;A Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>
FACULTY 2020

Yehuda Handelsman, MD, FACP
FNLA, FASPC, MACE
Chair
Medical Director & Principal Investigator
The Metabolic Institute of America
Chair & Program Director, WCIRD
Chair & Founder
International Committee for Insulin Resistance
Tarzana, California

Monica Aggarwal, MD
Associate Professor, Division of Cardiology
Director of Integrative Cardiology and Prevention
University of Florida/Shands Hospital
Gainesville, Florida

Richard M. Bergenstal, MD
Executive Director
International Diabetes Center
Saint Louis Park, Minnesota

Richard N. Bergman, PhD
Alfred Joy Firestein Chair in Diabetes Research
Professor, Department of Biomedical Sciences
Cedars-Sinai
Director, Sports Spectacular Diabetes and Obesity Wellness and Research Center
Professor-in-Residence, Department of Medicine
Los Angeles, California

Deepak L. Bhatt, MD
MPH, FACC FAHA, FSCAI, FESC
Executive Director of Interventional Cardiovascular Programs,
Brigham and Women's Hospital Heart & Vascular Center
Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Zachary T. Bloomgarden, MD, MACE
Clinical Professor
Department of Medicine
Icahn School of Medicine at Mount Sinai
Editor, The Journal of Diabetes
New York, New York

Stefan Bornstein, PhD
Chair of Medicine, Internal Medicine,
University Clinic Dresden and
Dean of the transCampus initiative

Matthew J. Budoff, MD, FACC, FAHA
Professor of Medicine
UCLA School of Medicine
Endowed Chair of Preventive Cardiology
Lundquist Institute
Los Angeles, California

Javed Butler, MD, MPH, MBA
Patrick H. Lehan Chair in Cardiovascular Research
Professor and Chairman
Department of Medicine
University of Mississippi Medical Center
Jackson, Mississippi

Sonia Caprio, MD
Professor of Pediatric Endocrinology
Yale University School of Medicine
New Haven, Connecticut

David Cherney, MD
CM, PhD, FRCPG
Senior Scientist,
Toronto General Hospital Research Institute
University Health Network
Associate Professor
Toronto, Ontario

Robert J. Chilton, DO, FACP
FACC, FAHA, MACOI, FASCAI
Professor of Medicine
Department of Medicine
Division of Cardiology
The University of Texas Health Science Center
San Antonio, Texas

Maria Rosa Costanzo, MD
FAHA, FACC, FESC
Medical Director, Heart Failure Research,
Advocate Heart Institute
Medical Director, Edward Hospital Center for Advanced Heart Failure
Naperville, Illinois

Kenneth Cusi, MD, FACP, FACE
Professor of Medicine
The University of Florida at Gainesville
Gainesville, Florida

Jaime A. Davidson, MD, FACP, MACE
Clinical Professor of Medicine
Division of Endocrinology
Diabetes and Metabolism
Touchstone Diabetes Research Center
The University of Texas Southwestern Medical Center
Dallas, Texas

Ralph A. DeFranzo, MD
Professor of Medicine
Chief, Diabetes Division
University of Texas Health Science Center at San Antonio (UTHSCSA)
San Antonio, Texas

Robert H. Eckel, M.D., FAHA, FACC
Professor of Medicine, Emeritus
Division of Endocrinology
Metabolism and Diabetes
Division of Cardiology
Charles A. Boettcher II Endowed Chair in Atherosclerosis, Emeritus
University of Colorado Anschutz Medical Campus
Past President, American Heart Association
President of Science and Medicine
American Diabetes Association
Denver Aurora, Colorado

Daniel Einhorn, MD, FACP, FACE
Chief, Diabetes and Endocrine Associates
Medical Director
Scripps Whittier Diabetes Institute
Clinical Professor, UCSD School of Medicine
La Jolla, California

Ronald M. Evans, PhD
Professor of Medicine
Director
Salk Institute for Biological Studies
La Jolla, California

Brendan M. Everett, MD, MPH
Associate Professor,
Harvard Medical School
Division of Cardiovascular Medicine
Brigham and Women's Hospital
Boston, Massachusetts

Vivian A. Fonseca, MD, FRCP
Professor of Medicine and Pharmacology
Assistant Dean for Clinical Research
Tulsa Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, Louisiana

Emily Jane Gallagher, MD, PhD
Assistant Professor of Medicine, Endocrinology,
Diabetes and Bone Disease
Associate Program Director for Internal Medicine Residency
Director of Research Track, Internal Medicine Residency Program
Department of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York
FACULTY 2020

W. Timothy Garvey, MD
Butterworth Professor
Department of Nutrition Sciences
University of Alabama at Birmingham
Director, UAB Diabetes Research Center
Birmingham, Alabama

Francesco Giorgino, MD, PhD
President, Italian Society of Endocrinology (SIE)
Professor of Endocrinology
Chairman, Department of Emergency and Organ Transplantation
Head, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases
University of Bari Aldo Moro
Chief, Division of Endocrinology
University Hospital PoliClinico Consorziale
Milano, Italy

Peter J. Grant, MD, FRCP, FMedsC
Professor of Medicine
Honorary Consultant Physician
University of Leeds
Leeds Teaching Hospitals NHS Trust
Division of Cardiovascular & Diabetes Research
LIGHT Laboratories
Leeds, United Kingdom

George Grunberger, MD
FACP, MACE
Chairman, Grunberger Diabetes Institute
Clinical Professor, Internal Medicine and Molecular Medicine & Genetics
Wayne State University School of Medicine
Professor, Internal Medicine
Oakland University William Beaumont School of Medicine
School of Medicine
Bloomfield Hills, Michigan

Martha Gulati MD, MS, FACC, FAHA
Editor-in-Chief, CardioSmart
Phoenix, Arizona

Kevin D. Hall, PhD
Senior Investigator
Integrative Physiology Section, Laboratory of Biological Modeling
Bethesda, Maryland

Kevan C. Herold, MD
C.N.H. Long Professor of Immunobiology and of Medicine
Deputy Director, Yale Center for Clinical Investigation
Yale University
New Haven, Connecticut

Howard N. Hodos, MD
Harry J. Bauer and Dorothy Bauer Rawlins Professor of Cardiology
Professor of Medicine and Preventive Medicine
Professor of Molecular Pharmacology and Toxicology
Director, Atherosclerosis Research Unit
Division of Cardiovascular Medicine
Keck School of Medicine
University of Southern California

Thomas Inge, MD, PhD
Professor of Surgery and Pediatrics
Associate Surgeon-in-Chief
Akers Endowed Chair and Director of Pediatric Surgery
Children’s Hospital Colorado and University of Colorado
Denver, Colorado

Paul S. Jellinger, MD, MACE
Professor of Clinical Medicine
Voluntary Faculty
University of Miami, Miller School of Medicine
The Center for Diabetes & Endocrine Care
Past President, AACE & ACE
Hollywood, Florida

Sanjay Kaul, MD, FACC, FAHA
Professor of Medicine,
Division of Cardiology
Cedars-Sinai Medical Center
David Geffen School of Medicine at UCLA
Ronald Reagan UCLA Medical Center
Fellow, American Heart Association
Fellow, American College of Cardiology
Los Angeles, California

Aaron S. Kelly, PhD
Professor, Department of Pediatrics
Co-Director, Center for Pediatric Obesity Medicine
University of Minnesota Medical School
Minneapolis, Minnesota

Samuel Klein, MD
William H. Danforth Professor of Medicine and Nutritional Science
Director, Center for Human Nutrition
Washington University School of Medicine
St. Louis, Missouri

Marta Koch, PhD
Editor-in-Chief
The Lancet Diabetes & Endocrinology
London, England

Mikhail N. Kosiborod MD
FACC, FAHA
Professor of Medicine
Saint Luke’s Mid America Heart Institute
University of Missouri-Kansas City School of Medicine
Kansas City, Missouri

Ronald M. Krauss, MD
Senior Scientist and Director
Atherosclerosis Research
Children’s Hospital Oakland Research Institute
Adjunct Professor
Department of Medicine, UCSF
Adjunct Professor
Department of Nutritional Sciences
University of California, Berkeley

Carolyn Lam Su Ping, MBBS, PhD
MRCP, MS, FACC, FAMS, FESC
Senior Consultant Cardiologist,
National Heart Centre Singapore
Professor, Duke-NUS Medical School
Singapore

Norman E. Lepor, MD
FACC, FAHA, FSCAI
Past President, California Chapter
American College of Cardiology
Clinical Professor of Medicine, Gelfen School of Medicine-UCLA
Attending Cardiologist
Cedars-Sinai Heart Institute
Co-director, Cardiovascular Imaging
Westside Medical Imaging
Director of Clinical Research
Westside Medical Associates
Los Angeles, California

Derek LeRoith, MD, PhD, FACP
Professor of Medicine
Director of Research
Division of Endocrinology
Diabetes & Bone Disease
Department of Medicine
Ichan School of Medicine at Mt. Sinai
New York, New York

Philip Levy, MD, MACE
Clinical Professor of Medicine,
University of Arizona College of Medicine
Endocrinologist
Banner University Medical Group
Phoenix, Arizona
FACULTY 2020

Gina P. Lundberg, MD, FACC, FAHA
Associate Professor of Medicine
Emory University School of Medicine
Clinical Director, Emory Women’s Heart Center
Atlanta, Georgia

Christos S. Mantzoros, MD, DSc, PhD h.c. mult.
Professor of Medicine,
Harvard Medical School and Boston University
School of Medicine
Chief of Endocrinology
Diabetes and Metabolism
Boston VA Healthcare System
Director of Human Nutrition, Beth Israel Deaconess Medical Center
Editor-in-Chief, Metabolism
Clinical & Experimental
Boston, Massachusetts

Nikolaus Marx, MD, FESC, FAHA
Professor of Medicine / Cardiology
Head of the Department of Internal Medicine
University Hospital RWTH Aachen
Aachen, Germany

Peter McCullough, MD, MPH
Professor of Medicine
Baylor Heart and Vascular Institute
Dallas, Texas

Tracey L. McLaughlin, MD, MS
Professor of Medicine
Division of Endocrinology
Stanford University School of Medicine
Stanford, California

Christian W. Mende, MD
FACP, FACN, FASN, FASH
Clinical Professor of Medicine
University of California San Diego
La Jolla, California

Erin Michos, MD, MHS
Director of Women’s Cardiovascular Health
Division of Cardiology
Johns Hopkins University School of Medicine
Baltimore, Maryland

Dimitri Mikhailidis, MD
Academic Head, Honorary Reader
and Honorary Consultant in the
Department of Molecular Pathology & Clinical Biochemistry
Royal Free Hospital campus, University College London Medical School
University College London (UCL), UK
Visiting Professor at Robert Gordon University
Aberdeen, Scotland

Geltrude Mingrone MD, PhD
Associate Professor of Internal Medicine
Catholic University of Rome, Italy
Professor of Diabetes and Nutrition
King’s College London
London, United Kingdom

David M. Nathan, MD
Director, Massachusetts General Hospital
Diabetes Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Ajay Nirula, MD, PhD
Vice President, Immunology
Eli Lilly & Co
San Diego, California

Neha J. Pagidipati, MD, MPH
Assistant Professor of Medicine
Division of Cardiology
Duke Clinical Research Institute
Durham, North Carolina

Jorge Plutzky, MD
Director, Preventive Cardiology
Cardiovascular Medicine
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts

Richard E. Pratley, MD
Samuel E. Crockett Chair in Diabetes Research,
Senior Investigator and Diabetes Program Lead
AdventHealth Translational Research Institute
Adjunct Professor of Medicine
Johns Hopkins University School of Medicine
Orlando, Florida

Kausik Ray, BS(hons), MBChB, MD, MPhil (Cantab), FRCP (Lon), FRCP (Ed), FACC, FESC, FAHA
Professor of Public Health/Consultant Cardiologist
Deputy Director of The Imperial Clinical Trials Unit Head of Commercial Trials
Department of Public Health and Primary Care
School of Public Health, Imperial College
Chief Clinical Officer and Head of Trials — Discover Now
NIHR ARC National Lead of Cardiovascular Disease
EAS President Elect
London, United Kingdom

Peter Reaven, MD
Professor of Clinical Medicine
University of Arizona
Phoenix, Arizona

Robert Rosenson, MD
Professor of Medicine (Cardiology)
Mount Sinai Icahn School of Medicine
Director, Cardiometabolics Unit
Mount Sinai Heart
New York, New York

Julio Rosenstock, MD
Director, Dallas Diabetes Research Center
Medical City Dallas
Clinical Professor of Medicine
University of Texas Southwest Medical Center
Dallas, Texas

Jerome I. Rotter, MD
Investigator, The Lundquist Institute
Director, Institute for Translational Genomics and Population Sciences,
Harbor-UCLA Medical Center
Professor of Pediatrics, Medicine and Human Genetics
David Geffen School of Medicine at UCLA
Los Angeles, California

Arun J. Sanyal, MBBS, MD
Professor of Medicine
Physiology and Molecular Pathology
Division of Gastroenterology
Hepatology and Nutrition
VCU Medical Center
Director, Education Core, CCTR
Virginia Commonwealth University
Richmond, Virginia
Philip R. Schauer MD  
FACS, FASMBS  
Mary Kay and Terrell Brown/Harris J. Chustz Chair  
Professor of Metabolic Surgery  
Pennington Biomedical Research Center  
at Louisiana State University  
Baton Rouge, Louisiana

Philipp E. Scherer, PhD  
Touchstone Diabetes Center  
The University of Texas Southwestern Medical Center  
Dallas, Texas

Gerald I. Shulman, MD, PhD  
George R. Cowgill Professor of Medicine (Endocrinology)  
Professor of Medicine and Cellular & Molecular Physiology  
Co-Director Yale Diabetes Research Center  
Yale University School of Medicine  
New Haven, Connecticut

Alan R. Sinaiko, MD  
Professor, Department of Pediatrics  
Division of Pediatric Nephrology  
University of Minnesota Medical School  
Minneapolis, Minnesota

Jay S. Skyler, MD, MACP  
Professor of Medicine  
Pediatrics and Psychology  
Deputy Director, Diabetes Research Institute  
University of Miami  
Miami, Florida

Michael P. Snyder, PhD  
Professor and Chair of Genetics  
Director, Center for Genomics and Personalized Medicine  
Stanford University School of Medicine  
Stanford, California

James Sowers, MD  
Director, Diabetes and Cardiovascular Center  
Professor of Physiology  
Pharmacology and Medicine  
Dalton Cardiovascular Research Center  
University of Missouri  
Columbia, Missouri

Bart Staels, PhD  
Full Professor, University of Lille  
Director of Inserm UMR1011 European Genomics Institute for Diabetes  
Institute Pastuer de Lille  
Lille, France

Katherine R. Tuttle, MD  
FASN, FACP, FNKF  
Executive Director for Research  
Providence Health Care  
Professor of Medicine, University of Washington  
Co-Principal Investigator, Institute of Translational Health Sciences

Muthiah Vaduganathan, MD, MPH  
Cardiologist, Brigham and Women’s Hospital,  
Harvard Medical School  
Boston, Massachusetts

Gerald F Watts DSc, PhD, DM  
FRACP, FRCP  
Winthrop Professor Cardio-Metabolic and Internal Medicine  
Royal Perth Hospital  
University of Western Australia  
Perth, Australia

Matthew R. Weir, MD  
Professor and Chief  
Division of Nephrology  
Department of Medicine  
University of Maryland School of Medicine  
Baltimore, Maryland

Paul Zimmet AO, MD, PhD  
Professor of Diabetes  
Monash University  
Melbourne, Australia

THE INTERNATIONAL COMMITTEE FOR INSULIN RESISTANCE GRATEFULLY ACKNOWLEDGES

PREMIER EDUCATOR  
AstraZeneca

LEADER EDUCATOR  
Abbott • Amarin

MAJOR EDUCATOR  
Lilly • Merck

EDUCATOR  
Novo Nordisk Zealand Pharma

CORPORATE SUPPORT

OPAL LEVEL  
Esperion • Amgen

EMERALD LEVEL  
Abbott • Amarin  
Boehringer Ingelheim/Lilly USA  
Lilly • Novartis
CME ACCREDITATION
For CME questions related to WCIRDC, please contact our CME Coordinator Renee Asp at renee@aspencmehelp.com

This activity was planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of PESI Inc. and the Metabolic Endocrine Education Foundation (MEEF). PESI Inc. is accredited by the ACCME to provide continuing medical education for physicians.

AMA PRA DESIGNATION STATEMENT
PESI Inc. has designated this live activity for a maximum of 33.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

MOC POINTS WITH ABIM
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn MOC points of Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Total qualifying MOC credits TBA.

FAMILY PHYSICIANS
Application for CME credit has been filed with the American Academy of Family Physicians.

INTERNATIONAL CME
International Physicians are formally eligible for AMA PRA Category 1 Credit™.

PHYSICIAN ASSISTANTS
AAPA accepts Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ for the PRA from organizations accredited by ACCME.

NURSES
For the purpose of re-certification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured learning activities.

CA NURSES
Aspen CME Services is approved by the California Board of Registered Nursing, provider number CEP14739, designated the 18th WCIRDC for contact hours - total hours TBA.

PHARMACISTS
For the purpose of re-certification, the American Council of Pharmacy Education accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured learning activities.

CDE
The National Certification Board for Diabetes Educators recognizes courses sponsored by PESI Inc. as approved ACCME provider. Total qualifying continuing education hours TBA.

REGISTERED DIETITIANS
For the purpose of re-certification, the Commission on Dietetic Registration recognizes courses accredited with AMA PRA Category 1 Credit™.

SATISFACTORY COMPLETION FOR CREDITS
All attendees must have completed and turned in a course attendance/evaluation form prior to leaving the conference. Each session claimed for credit must be attended in its entirety.
WCIRDC PARTNERS & ENDORSING ORGANIZATIONS

Media Partners

- Metabolism (Elsevier)
- The Lancet Diabetes & Endocrinology
- Healio: Cardiology Today & Endocrine Today
- Bentham Science
- Cardiovascular Endocrinology & Metabolism (Wolters Kluwer)
- CN1699
- ConferenceLocate.com
- Diabetes & Vascular Disease Research (Sage)
- Diabetes in Control
- Elsevier
- Endocrine Web
- Endocrinology Advisor
- Hindawi
- Journal of Diabetes
- MIMS
- MJH Life Sciences (American Journal of Managed Care & HCPLive Network)
- PharmaVoice
- Physician’s Weekly
- Sage Publishing
- VenueDir
- Vessel Plus

Participating Organizations

- American Diabetes Association (ADA)
- American Society for Preventive Cardiology (ASPC)
- American Association of Diabetes Educators (AADE)
- American Society for Nutrition (ASN)
- American Society of Endocrine Physician Assistants (ASEPA)
- Association of Diabetes Care & Education Specialists (ADCES)
- California Chapter of the American College of Cardiology (CAACC)
- Endocrine Nurses Society (ENS)
- Familial Hypercholesterolemia (FH) Foundation
- International Academy of Cardiology (IAC)
- International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO)
- Israel Endocrine Society (IES)
- Pacific Lipid Association
- Point of Care Network (POCN)
- Society for Vascular Surgery (SVS)
- World Obesity Federation

FOR ADDITIONAL INFORMATION ON

Registration | Support | Exhibits
(818) 432-1889 | info@tmioa.com | www.WCIR.ORG

Save the Date • 19th WCIRDC • December 2–4, 2021
Hilton Universal City I Hotel Los Angeles, California